These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 21796083)

  • 1. Residual risk and high-density lipoprotein cholesterol levels: is there a relationship?
    Shah PK
    Rev Cardiovasc Med; 2011; 12(2):e55-9. PubMed ID: 21796083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
    Ferrières J; Bérard E; Crisan O; Bongard V
    Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid abnormalities and cardiovascular risk in the elderly.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].
    Soska V
    Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treating dyslipidemia in the high-risk patient.
    Jones PH
    J Fam Pract; 2010 Feb; 59(2):E1. PubMed ID: 20141719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should raising high-density lipoprotein cholesterol be a matter of debate?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    J Cardiovasc Med (Hagerstown); 2012 Apr; 13(4):254-9. PubMed ID: 22367577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-density lipoprotein cholesterol and triglycerides in the statin era: a pending issue?
    Paillard F
    Arch Cardiovasc Dis; 2009 Mar; 102(3):165-7. PubMed ID: 19375669
    [No Abstract]   [Full Text] [Related]  

  • 9. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ; Lundman P; Tardif JC
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?
    Zoungas S; Curtis AJ; McNeil JJ; Tonkin AM
    Clin Pharmacol Ther; 2014 Aug; 96(2):192-205. PubMed ID: 24727468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Statins in the management of dyslipidemias].
    Scheen AJ
    Rev Prat; 2011 Oct; 61(8):1120-6. PubMed ID: 22135981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-density lipoprotein levels and risk of cardiovascular events: a review.
    Mureddu GF; Brandimarte F; De Luca L
    J Cardiovasc Med (Hagerstown); 2012 Sep; 13(9):575-86. PubMed ID: 21986488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond statin therapy: why we need new thinking.
    Assmann G
    Curr Med Res Opin; 2005; 21 Suppl 6():S3-8. PubMed ID: 16138935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Niacin's role in the statin era.
    Brooks EL; Kuvin JT; Karas RH
    Expert Opin Pharmacother; 2010 Oct; 11(14):2291-300. PubMed ID: 20569085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-density lipoprotein cholesterol: current perspective for clinicians.
    Whayne TF
    Angiology; 2009; 60(5):644-9. PubMed ID: 19240106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.